Efeito farmacogenético e farmacogenômico do metotrexato na citotoxicidade de células mononucleares periféricas do sangue

Detalhes bibliográficos
Autor(a) principal: Barbisan, Fernanda
Data de Publicação: 2014
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Manancial - Repositório Digital da UFSM
Texto Completo: http://repositorio.ufsm.br/handle/1/9011
Resumo: Methotrexate (MTX) is an antimetabolite drug analogue of folic acid with wide clinical application, used in high doses for the treatment of cancer and in low doses for the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis. Although effective, the MTX has several side effects. The oxidative stress seems to be involved with the toxicity caused by the MTX in various organs. Despite the effect on the imbalance of oxidative metabolism, the influence of polymorphisms of antioxidant enzymes on MTX toxicity is not well studied. In this context, the present study aimed to examine whether the Ala16Val polymorphism of the antioxidant enzyme superoxide dismutase manganese dependent (SOD2), which affects the efficiency of the detox enzyme, could have an effect on the cytotoxic response to MTX. For this, an in vitro study using peripheral blood mononuclear cells (PBMC) obtained from healthy donors harboring different genotypes of polymorphism Ala16Val-SOD (= genotypes AA, VV and AV) was performed. Once obtained, PBMCs were treated with MTX at concentrations of 10 and 100 μM for 24 and 72 hours and analyzed for the effect on viability, modulation of the oxidative metabolism-inflammatory and apoptotic. PBMC-AA which have a naturally SOD2 30 to 40% more efficient than the PBMC- VV, showed more resistance to treatment with MTX compared to PBMC-AV/VV assessed. As production levels of EROS and lipid peroxidation significantly increased in cells exposed to MTX, regardless of genotype, however, increased levels of protein carbonylation were observed only in PBMC-AV/VV. The PBMC-AA demonstrated decreased activity of SOD2 and the levels of glutathione peroxidase with PBMC-AA were higher. The levels of caspase-8 and -3 were increased in PBMC exposed to MTX, but the modulation of these genes, as well as Bax and Bcl-2 genes involved in apoptotic route, was genotype dependent. The MTX was able to raise the levels of inflammatory cytokines and decrease the level of anti-inflammatory cytokine IL-10, regardless of genotype. The results suggest that Ala16Val-SOD2 polymorphism is capable of modulating the cytotoxic response of PBMC to the MTX.
id UFSM_1f66700ff7cc4251f97c4f515a627586
oai_identifier_str oai:repositorio.ufsm.br:1/9011
network_acronym_str UFSM
network_name_str Manancial - Repositório Digital da UFSM
repository_id_str
spelling Efeito farmacogenético e farmacogenômico do metotrexato na citotoxicidade de células mononucleares periféricas do sangueMetotrexatoSuperóxidoToxicidadeMarcadores oxidativos e inflamatóriosMethotrexateSuperoxideToxicityOxidative and inflammatory markersCNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIAMethotrexate (MTX) is an antimetabolite drug analogue of folic acid with wide clinical application, used in high doses for the treatment of cancer and in low doses for the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis. Although effective, the MTX has several side effects. The oxidative stress seems to be involved with the toxicity caused by the MTX in various organs. Despite the effect on the imbalance of oxidative metabolism, the influence of polymorphisms of antioxidant enzymes on MTX toxicity is not well studied. In this context, the present study aimed to examine whether the Ala16Val polymorphism of the antioxidant enzyme superoxide dismutase manganese dependent (SOD2), which affects the efficiency of the detox enzyme, could have an effect on the cytotoxic response to MTX. For this, an in vitro study using peripheral blood mononuclear cells (PBMC) obtained from healthy donors harboring different genotypes of polymorphism Ala16Val-SOD (= genotypes AA, VV and AV) was performed. Once obtained, PBMCs were treated with MTX at concentrations of 10 and 100 μM for 24 and 72 hours and analyzed for the effect on viability, modulation of the oxidative metabolism-inflammatory and apoptotic. PBMC-AA which have a naturally SOD2 30 to 40% more efficient than the PBMC- VV, showed more resistance to treatment with MTX compared to PBMC-AV/VV assessed. As production levels of EROS and lipid peroxidation significantly increased in cells exposed to MTX, regardless of genotype, however, increased levels of protein carbonylation were observed only in PBMC-AV/VV. The PBMC-AA demonstrated decreased activity of SOD2 and the levels of glutathione peroxidase with PBMC-AA were higher. The levels of caspase-8 and -3 were increased in PBMC exposed to MTX, but the modulation of these genes, as well as Bax and Bcl-2 genes involved in apoptotic route, was genotype dependent. The MTX was able to raise the levels of inflammatory cytokines and decrease the level of anti-inflammatory cytokine IL-10, regardless of genotype. The results suggest that Ala16Val-SOD2 polymorphism is capable of modulating the cytotoxic response of PBMC to the MTX.Coordenação de Aperfeiçoamento de Pessoal de Nível SuperiorO Metotrexato (MTX) é um fármaco antimetabólito análogo do ácido fólico, com vasta aplicação clinica, utilizado em doses elevadas no tratamento de neoplasias e em baixas doses para o tratamento de doenças autoimunes, como a artrite reumatoide e a psoríase. Apesar de efetivo, o MTX possui diversos efeitos colaterais. Assim, o estresse oxidativo parece estar envolvido com a toxicidade causada pelo MTX a diversos órgãos. Apesar do efeito no desequilíbrio do metabolismo oxidativo, a influência de polimorfismos de enzimas antioxidantes sobre a toxicidade ao MTX ainda não é bem estudada. Nesse contexto, o presente estudo teve como objetivo analisar se o polimorfismo Ala16Val da enzima antioxidante superóxido dismutase dependente de manganês (SOD2), que afeta a eficiência detoxificadora da enzima, poderia ter efeito sobre a resposta citotóxica ao MTX. Para tanto, foi realizado um estudo in vitro utilizando células mononucleares do sangue periférico (CMSP), obtidas de doadores saudáveis portadores de diferentes genótipos do polimorfismo Ala16Val-SOD (genótipos = AA, VV e AV). Uma vez obtidas, as CMSPs foram tratadas com MTX nas concentrações de 10 e 100 μM por 24 e 72 horas, sendo posteriormente analisado o efeito sobre a viabilidade, modulação do metabolismo oxidativo-inflamatório e apoptótico. As CMSP-AA, que naturalmente apresentam uma SOD2 30 a 40% mais eficiente do que as CMSP-VV, apresentaram maior resistência ao tratamento com MTX em relação às CMSP-AV/VV. Quanto aos níveis de produção de EROS (espécies reativas de oxigênio) e lipoperoxidação, houve aumento significativo nas células expostas ao MTX independente do genótipo, entretanto, o aumento dos níveis de carbonilação de proteínas foi observado apenas em CMSP-AV/VV. Nas CMSP-AA houve diminuição da atividade da SOD2. Já quanto aos níveis de Glutationa Peroxidase, as CMSP-AA apresentaram uma elevação mais intensa. Os níveis das caspases 3 e 8 foram aumentados nas CMSP expostas ao MTX, mas a modulação desses genes, assim como do Bax e Bcl-2 (genes envolvidos rota apoptótica), foi genótipo-dependente. O MTX foi capaz de elevar os níveis das citocinas inflamatórias e diminuir o nível da citocina antiinflamatória IL-10, independente do genótipo. Os resultados sugerem que o polimorfismo Ala16Val-SOD2 é capaz de modular a resposta citotóxica de CMSP ao MTX.Universidade Federal de Santa MariaBRFarmacologiaUFSMPrograma de Pós-Graduação em FarmacologiaCruz, Ivana Beatrice Mânica dahttp://lattes.cnpq.br/3426369324110716Rocha, Maria Izabel de Ugalde Marques dahttp://lattes.cnpq.br/8282487927775392Wagner, Glauberhttp://lattes.cnpq.br/8417542717418294Barbisan, Fernanda2015-04-302015-04-302014-07-18info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfapplication/pdfBARBISAN, Fernanda. Efeito farmacogenético e farmacogenômico do metotrexato na citotoxicidade de células mononucleares periféricas do sangue. 2014. 82 f. Dissertação (Mestrado em Farmácia) - Universidade Federal de Santa Maria, Santa Maria, 2014.http://repositorio.ufsm.br/handle/1/9011porinfo:eu-repo/semantics/openAccessreponame:Manancial - Repositório Digital da UFSMinstname:Universidade Federal de Santa Maria (UFSM)instacron:UFSM2024-07-16T14:25:43Zoai:repositorio.ufsm.br:1/9011Biblioteca Digital de Teses e Dissertaçõeshttps://repositorio.ufsm.br/ONGhttps://repositorio.ufsm.br/oai/requestatendimento.sib@ufsm.br||tedebc@gmail.comopendoar:2024-07-16T14:25:43Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)false
dc.title.none.fl_str_mv Efeito farmacogenético e farmacogenômico do metotrexato na citotoxicidade de células mononucleares periféricas do sangue
title Efeito farmacogenético e farmacogenômico do metotrexato na citotoxicidade de células mononucleares periféricas do sangue
spellingShingle Efeito farmacogenético e farmacogenômico do metotrexato na citotoxicidade de células mononucleares periféricas do sangue
Barbisan, Fernanda
Metotrexato
Superóxido
Toxicidade
Marcadores oxidativos e inflamatórios
Methotrexate
Superoxide
Toxicity
Oxidative and inflammatory markers
CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA
title_short Efeito farmacogenético e farmacogenômico do metotrexato na citotoxicidade de células mononucleares periféricas do sangue
title_full Efeito farmacogenético e farmacogenômico do metotrexato na citotoxicidade de células mononucleares periféricas do sangue
title_fullStr Efeito farmacogenético e farmacogenômico do metotrexato na citotoxicidade de células mononucleares periféricas do sangue
title_full_unstemmed Efeito farmacogenético e farmacogenômico do metotrexato na citotoxicidade de células mononucleares periféricas do sangue
title_sort Efeito farmacogenético e farmacogenômico do metotrexato na citotoxicidade de células mononucleares periféricas do sangue
author Barbisan, Fernanda
author_facet Barbisan, Fernanda
author_role author
dc.contributor.none.fl_str_mv Cruz, Ivana Beatrice Mânica da
http://lattes.cnpq.br/3426369324110716
Rocha, Maria Izabel de Ugalde Marques da
http://lattes.cnpq.br/8282487927775392
Wagner, Glauber
http://lattes.cnpq.br/8417542717418294
dc.contributor.author.fl_str_mv Barbisan, Fernanda
dc.subject.por.fl_str_mv Metotrexato
Superóxido
Toxicidade
Marcadores oxidativos e inflamatórios
Methotrexate
Superoxide
Toxicity
Oxidative and inflammatory markers
CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA
topic Metotrexato
Superóxido
Toxicidade
Marcadores oxidativos e inflamatórios
Methotrexate
Superoxide
Toxicity
Oxidative and inflammatory markers
CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA
description Methotrexate (MTX) is an antimetabolite drug analogue of folic acid with wide clinical application, used in high doses for the treatment of cancer and in low doses for the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis. Although effective, the MTX has several side effects. The oxidative stress seems to be involved with the toxicity caused by the MTX in various organs. Despite the effect on the imbalance of oxidative metabolism, the influence of polymorphisms of antioxidant enzymes on MTX toxicity is not well studied. In this context, the present study aimed to examine whether the Ala16Val polymorphism of the antioxidant enzyme superoxide dismutase manganese dependent (SOD2), which affects the efficiency of the detox enzyme, could have an effect on the cytotoxic response to MTX. For this, an in vitro study using peripheral blood mononuclear cells (PBMC) obtained from healthy donors harboring different genotypes of polymorphism Ala16Val-SOD (= genotypes AA, VV and AV) was performed. Once obtained, PBMCs were treated with MTX at concentrations of 10 and 100 μM for 24 and 72 hours and analyzed for the effect on viability, modulation of the oxidative metabolism-inflammatory and apoptotic. PBMC-AA which have a naturally SOD2 30 to 40% more efficient than the PBMC- VV, showed more resistance to treatment with MTX compared to PBMC-AV/VV assessed. As production levels of EROS and lipid peroxidation significantly increased in cells exposed to MTX, regardless of genotype, however, increased levels of protein carbonylation were observed only in PBMC-AV/VV. The PBMC-AA demonstrated decreased activity of SOD2 and the levels of glutathione peroxidase with PBMC-AA were higher. The levels of caspase-8 and -3 were increased in PBMC exposed to MTX, but the modulation of these genes, as well as Bax and Bcl-2 genes involved in apoptotic route, was genotype dependent. The MTX was able to raise the levels of inflammatory cytokines and decrease the level of anti-inflammatory cytokine IL-10, regardless of genotype. The results suggest that Ala16Val-SOD2 polymorphism is capable of modulating the cytotoxic response of PBMC to the MTX.
publishDate 2014
dc.date.none.fl_str_mv 2014-07-18
2015-04-30
2015-04-30
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv BARBISAN, Fernanda. Efeito farmacogenético e farmacogenômico do metotrexato na citotoxicidade de células mononucleares periféricas do sangue. 2014. 82 f. Dissertação (Mestrado em Farmácia) - Universidade Federal de Santa Maria, Santa Maria, 2014.
http://repositorio.ufsm.br/handle/1/9011
identifier_str_mv BARBISAN, Fernanda. Efeito farmacogenético e farmacogenômico do metotrexato na citotoxicidade de células mononucleares periféricas do sangue. 2014. 82 f. Dissertação (Mestrado em Farmácia) - Universidade Federal de Santa Maria, Santa Maria, 2014.
url http://repositorio.ufsm.br/handle/1/9011
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de Santa Maria
BR
Farmacologia
UFSM
Programa de Pós-Graduação em Farmacologia
publisher.none.fl_str_mv Universidade Federal de Santa Maria
BR
Farmacologia
UFSM
Programa de Pós-Graduação em Farmacologia
dc.source.none.fl_str_mv reponame:Manancial - Repositório Digital da UFSM
instname:Universidade Federal de Santa Maria (UFSM)
instacron:UFSM
instname_str Universidade Federal de Santa Maria (UFSM)
instacron_str UFSM
institution UFSM
reponame_str Manancial - Repositório Digital da UFSM
collection Manancial - Repositório Digital da UFSM
repository.name.fl_str_mv Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)
repository.mail.fl_str_mv atendimento.sib@ufsm.br||tedebc@gmail.com
_version_ 1805922079171674112